Zhittaya June 2023 update

[Jmellano]

For those who are interested in Zhittya, They have cocceded that their process does NOT reverse PArkinson's see june update email

[Bolt_Upright]

At some point they should post this June update to their website zgm.care/news

Important: An Update to Our Parkinson’s Disease Hypothesis

Zhittya has been confronted with the reality that putting trillions of FGF-1 molecules into the brain by dosing once per day for seven days (which we believed would trigger enough angiogenesis and neurogenesis to reverse Parkinson’s disease) is not working! In previous studies, Zhittya observed that when FGF-1 was injected directly into a specific area of ischemic heart muscle, it initiated an amazing biological response that created enough new blood vessels to successfully treat no-option heart disease.

We applied this same hypothesis to our efforts in the brain. In the first 60 days after intranasal dosing Parkinson’s disease patients with FGF-1, we saw an incredible improvement in the motor skills of these subjects, on average, over a 50% improvement in their motor skills. Patients also reported enhanced memory and brain functions after the FGF-1 treatment. We had assumed that like in the heart, the targeted area in the brain (the substantia nigra) would get enough FGF-1 to regenerate the dopamine producing neurons and that the improvement would continue to occur over many months, hopefully reversing Parkinson’s disease completely. However, as now that approximately 25 of our first test subjects have had their 6-month motor skill testing, we find that this is not happening.

After the first surge of their improvement (from zero to 60 days) noted by patients following their initial dosing with FGF-1, most test subjects reported a leveling off of their improvement rate in months 3–6, with only small improvements noted during that period. This is similar to what was seen in the monkeys who had been given experimental Parkinson’s disease and then given FGF-1 to improve their motor skills. Since the monkeys were terminated at 7 months, we had hoped the recovery in humans would continue after that time and so far, it has not.

Reality is always an unpleasant master. As noted above, we saw great improvement in test subjects' motor skills from the first dosing until 30 to 60 days later, then improvements flattened out. People did not get worse; they just did not improve as much as our research indicated they should improve. Something was wrong with our hypotheses and our calculations; trillions of FGF-1 molecules never reached the substantia nigra, as we had forecasted, and we just did not know why.

During our numerous Medical Research Studies in the British Virgin Islands to treat Parkinson’s disease sufferers, we had many interesting anecdotal events that test subjects reported to us. Many people reported their senses of smell and taste had returned to them. When we thought about it, it made sense, since we are sending trillions of FGF-1 molecules along the olfactory nerve into the olfactory bulb of the brain in our attempt to get FGF-1 to the substantia nigra area of the brain. The idea that trillions of FGF-1 molecules traveling over stressed neurons in the olfactory nerve and in the olfactory bulb could be taken up by those stressed cells and could then trigger their regeneration now makes obvious sense after you think about it.

Several people told us that some of their vision issues had cleared up. Well, some FGF-1 could have easily migrated to the optic nerve and do what FGF-1 is supposed to do, regenerate neurons. People tell us that their short-term memory has improved, and we know the area of the brain which regulates short term memory is a long distance from the substantia nigra. All this makes sense when you consider the animal data we received from the University of Minnesota which showed that when you deliver FGF-1 up the nose, FGF-1 migrates to all areas of the brain.

When we decided to initiate studies to see if intranasally-administered FGF-1 can reverse type 2 diabetes (as reported in animal studies), we had to calculate how much FGF-1 we needed to get into the brain to trigger the desired effect. At that time, Dr. Jacobs started researching how much FGF-1 other brain cells could absorb, and the data he found is shocking! Later on in this update, you can read Dr. Jacobs’s section on how most cells in the brain suck up FGF-1, like water getting sucked up by the dry soil of the desert. Neurons, endothelial cells, astrocytes, and microglia all want FGF-1. We believe those stressed brain cells have been taking up a lot of the FGF-1 and have been using a substantial amount of the FGF-1 that we thought we were sending exclusively to the substantia nigra.

Dr. Jacobs’s research found that the trillions of FGF-1 molecules that have been taken up by other brain cells were ruining our math calculations. As if we poured a bucket of water into drought-stricken desert soil. The brain seems to be doing much the same thing with our FGF-1 as it passes throughout brain tissue, taking the FGF-1 into those cells for their own needs.

We now realize that older people may be suffering from an FGF-1 drought in their brains. Is the lack of FGF-1 why the brain of an older person shrivels up like a prune? Is this why neurodegenerative diseases affect older people, as their brains obtain less and less FGF-1 over time, which results in less blood flow and a decrease in blood vessel density in their brains?

We are now changing our hypothesis on how FGF-1 works in the brain and realize that we may need to dose multiple times with intranasal FGF-1 until we have corrected the deficits caused by this decades-long FGF-1 deficiency. We may need to dose people every three months for two years to correct conditions caused by an FGF-1 deficiency and return the brain to normal. To succeed and treat these brain disorders, we must follow reality, no matter where it takes us. Our mission, to heal the brain, is too important for us not to find the true needs of the brain. We now believe it may take years of FGF-1 dosing to repair decades of damage to the brain.

While the realization that trillions of the FGF-1 molecules are being taken up by other brain cells is a troubling reality, the good news is if those brain cells outside the substantia nigra needed FGF-1 to function properly, it is not a bad thing. If diminished quantities of FGF-1 lead to vascular dysfunction, or type 2 diabetes or confusion, dementia, etc., replenishing the FGF-1 in the entire brain should be a good thing.

[MBAnderson in reply to Bolt_Upright]

"Reality is always an unpleasant master." Indeed - unless you are onto to something that works

[Bolt_Upright in reply to MBAnderson]

"Reality is always an unpleasant master" is a great line Marc. Is that yours?

[1LittleWillow in reply to Bolt_Upright]

It's a quote taken from the update above... 5th or 6th paragraph.

[MBAnderson in reply to 1LittleWillow]

LittleWillow called it. (Ist sentence of the 4th para.)

[1LittleWillow in reply to MBAnderson]

I remembered it from having read the release the night before. The expression caught my ear as well.

[crewmanwhite]

It is better to discover the fundamental causes of each person's symptoms (which will be some combo of trauma, toxins and/or infection), then treat those causes.

It take effort and a long time, but it really works.

[Rupa88]

zhyttia was a big joke

[PDspouse22]

The treatment sounded very promising, but the methods used to "evaluate" the result are highly suspect and possibly subject to observer bias. If the molecule works, it will work without the subject or the evaluator knowing whether the real treatment or a sham/placebo was administered. The lack of a placebo group and blinded evaluators are major problems with the research design. From the limited information given, it appears that the investigators evaluated the motor results in a subjective manner. The subjects "reported" several other positive benefits, but anecdotal reports by subjects can be unreliable. I've read reports that subjects had to pay $50K plus travel costs to participate in the studies. I think if there was credible evidence this treatment improved Parkinson's, large Pharma companies would have been bidding many millions for the rights to this molecule if it could get patent protection. The big companies would have started rigorous clinical trials using accepted research methodology The lack of peer-reviewed studies is a HUGE red flag. The principals in the company include several of the CEO's family according to the company website I saw. 2 young people with the same last name as the CEO hold VP positions in the company and are in college working on undergraduate degrees.

zgm.care/about-us/zhittyas-...